Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.

Akito Hata,Isamu Okamoto,Naoki Inui,Morihito Okada,Masahiro Morise,Kohei Akiyoshi,Masayuki Takeda,Yasutaka Watanabe,Shunichi Sugawara,Naofumi Shinagawa,Kaoru Kubota,Toshiaki Saeki,Tomohide Tamura

Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.

2021

Akito Hata
Isamu Okamoto
Naoki Inui
Morihito Okada
Masahiro Morise
Kohei Akiyoshi
Masayuki Takeda
Yasutaka Watanabe
Shunichi Sugawara
Naofumi Shinagawa
Kaoru Kubota
Toshiaki Saeki
Tomohide Tamura

PURPOSEWe evaluated the efficacy and safety of fosnetupitant (FosNTP) versus fosaprepitant (FosAPR) for preventing highly emetogenic chemotherapy-induced nausea and vomiting. This phase III study w...

Keywords:

highly emetogenic chemotherapy
Fosaprepitant
Medicine
double blind
Vomiting
Anesthesia
Nausea

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations